Mary R. Welch, MD
- Assistant Professor of Neurology at CUMC
Mary Welch, MD is an Assistant Professor of Neurology at CUMC, in the Division of Neuro-Oncology. Dr. Welch graduated from Chicagos' Northwestern Feinberg School of Medicine. She completed neurology residency here at Columbia, followed by sub-specialty training in neuro-oncology at Memorial Sloan-Kettering Cancer Center. In her second year of fellowship, she earned a Comparative Effectiveness Research Award to attend Columbia's Summer Research Institute at Mailman School of Public Health.
Upon completing her training, Dr. Welch worked for several years as a practicing neuro-oncologist and Assistant Professor of Neurology at Montefiore Medical Center in the Bronx. There, she served as principal investigator for numerous phase I and II clinical trials for the treatment of primary and metastatic brain cancer. She also developed a strong research interest in improving patient access to both standard and investigational therapies. In addition to seeing both inpatient and outpatient neuro-oncology patients, Dr. Welch maintains an active research program within the Division of Neuro-Oncology.
- Department of Neurology
Division of Neuro-oncology
(in addition to English)
Education & Training
- MD, Northwestern University Feinberg School of Medicine
- Internship: New York University Langone Medical Center
- Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
- Fellowship: Memorial Sloan-Kettering Cancer Center
- Office Phone: (212) 342-0571
American Academy of Neurology, Member
Society for Neuro-Oncology, Member
American Society of Clinical Oncology, Member
Alliance for Clinical Trials in Oncology, Member
NRG Oncology, Member
Honors & Awards
ASCO Conquer Cancer Foundation Merit Award
Comparative Effectiveness Research Award
Arnold P. Gold Humanism and Excellence in Teaching Award
AN OPEN-LABEL, MULTI-CENTER TRIAL OF INO-5401 AND INO-9012 DELIVERED BY ELECTROPORATION (EP) IN COMBINATION WITH REGN2810 IN SUBJECTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA (GBM) (P&S Industry Clinical Trial)
Jul 6 2018 - Jul 6 2023
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF DSP-7888 DOSING EMULSION IN COMBINATION WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN PATIENTS WITH RECURRENT OR PROGRESSIVE GLIOBLASTOMA FOLLOWING INITIAL THERAPY (P&S Industry Clinical Trial)
Feb 6 2018 - Feb 6 2023
INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT) (P&S Industry Clinical Trial)
Dec 20 2017 - Dec 20 2021
INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT) - CONTROL ARM OF INSIGHT (Private)
Dec 1 2017 - Nov 30 2019
Pareek V, Welch M, Ravera E, Zampolin RL, Sequist LV, Halmos B. Marked differences in CNS activity amongst EGFR inhibitors: case report and mini-review. J Thorac Oncol. 2016 Jul 24 [Epub ahead of print]
Yang Y, Haigentz M, Welch M. Diplopia and Ataxia in a Heavy Smoker. JAMA 2015 September; 314(9):942-943.
Glover R, Brook A, Welch M. Teaching Neuroimages: Leptomeningeal carcinomatosis. Neurology 2014 May; 82(21): e183-4.
Welch M, Sauter C, Matasar M, Moskowitz C, Omuro A. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan, and cyclophosphamide. Leukemia and Lymphoma. 2015; 56(2):361-7.
Welch M, Grommes C. Influence of anti-diabetic therapy of diabetes mellitus type II (DM) on survival in glioblastoma (GBM) patients. CNS Oncology. 2013 2(3), 237–246.
Welch M, Omuro A, DeAngelis L. Outcomes of the Oldest Patients with Primary Central Nervous System Lymphoma Treated at Memorial Sloan-Kettering Cancer Center. Neuro-Oncology. 2012 Oct; 14(10):1304-11.